Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Bristol-Myers Squibb Company PFD CONV 2 (OTCPK:BMYMP) had declared $0.50/share quarterly dividend Payable Dec. 2; for shareholders of record Nov. 5; ex-div Nov. 5. See BMYMP Dividend Scorecard, Yield ...

Compounding pharmacies are typically allowed to make copies of drugs that are deemed to be in shortage by the FDA, which semaglutide has been for over two years. But Novo argued that semaglutide ...

In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults with schizophrenia. Citing new topline data from its 52-week open-label studies ...

After the recent FDA approval for the promising schizophrenia ... Patients on the drug, also known as KarXT, achieved a 16.9-point reduction on the scale, Zai Lab said. The improvement for those ...